Mount Sinai School of Medicine

...drug from the market. Led by Joseph Ross, MD, MHS, Assistant Professor of Geriatrics and Palliative Medicine and of Medicine at Mount Sinai School of Medicine, a team of six investigators analyzed 30 randomized, placebo-controlled trials...

In this article: Rofecoxib, FDA, Merck & Co., Plaintiff, American College of Cardiology, Medical advice, and Heart transplant

...according to Health Day. In later trials, the risk continued to increase, the group found. Lead author Joseph Ross, an assistant professor at Mount Sinai School of Medicine, says the U.S. drug approval process prevented the public from knowing...

In this article: Vioxx, Breast cancer, Allergy, Merck, Carcinoma, Carbohydrate, and Cancer

...24 Nov 2009 - 6:00 PST Geisinger Health System is one of only six healthcare organizations in the United States invited by the Mount Sinai School of Medicine and Johns Hopkins University to participate in a new pilot program, Medicare...

In this article: Medicare, Geisinger Health System, Medical advice, Johns Hopkins University, and United States

...even while the drug was being developed. September 2004 had seen the manufacturer withdraw the drug from the markets. Joseph S. Ross of Mount Sinai School of Medicine, New York and his team examined published and unpublished clinical trial...

In this article: Rofecoxib, Archives of Internal Medicine, Washington, and New York

...recognize these safety risks early," said lead researcher Dr. Joseph S. Ross, an assistant professor of geriatrics and palliative medicine at Mount Sinai School of Medicine in New York City. The trials that drug companies conduct to get U.S....

In this article: Rofecoxib, Merck & Co., Steven E. Nissen, FDA, Archives of Internal Medicine, New York City, and Bextra

...public," said the lead author of the study, Dr. Joseph S. Ross, an assistant professor of geriatrics and palliative medicine at New York's Mount Sinai School of Medicine. In research published in the Archives of Internal Medicine, Ross and...

In this article: Vioxx, Merck & Co., Anti-inflammatory, Hypertension, Food and Drug Administration, and Mount Sinai

...of Merck's own data suggests. The study, published in the current issue of the Archives of Internal Medicine, is by Joseph S. Ross, MD, of Mount Sinai School of Medicine, and colleagues. The study authors were paid consultants to plaintiffs'...

In this article: Merck, Vioxx, Plaintiff, Scientific method, Archives of Internal Medicine, Arthritis, and WebMD

...22 science laboratories at universities in 13 Latin American and African countries. The project has expanded to BU, Yale Medical School, Mount Sinai Medical School, and Albert Einstein College in New York. Dudnick also is working with...

In this article: Harvard, Boston Globe, Yale Medical School, HuffPost, Mount Sinai Medical School, and Facebook

...Hyun Yong Jeon, M.S., research assistant with the VCU Department of Human and Molecular Genetics; Luni Emdad, M.D., Ph. D., with the Mount Sinai School of Medicine in New York; and Habib Boukerche, Ph. D., a senior scientist with the...

In this article: Cancer, New York, Medical advice, Breast cancer, Neuroblastoma, and Lung cancer

Article Date: 19 Nov 2009 - 2:00 PST Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce...

In this article: Alzheimer's disease, Glucose, Medical advice, Diabetes mellitus, Carbohydrate, Peptide, Paralysis, and Creb-binding Protein